已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Ripretinib Versus Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumor After Treatment With Imatinib (INTRIGUE): A Randomized, Open-Label, Phase III Trial

医学 舒尼替尼 主旨 内科学 伊马替尼 危险系数 临床终点 胃肠病学 酪氨酸激酶抑制剂 甲磺酸伊马替尼 肿瘤科 无进展生存期 外科 随机对照试验 置信区间 癌症 间质细胞 化疗 髓系白血病
作者
Sebastian Bauer,Robin L. Jones,Jean‐Yves Blay,Hans Gelderblom,Suzanne George,Patrick Schöffski,Margaret von Mehren,John Zalcberg,Yoon‐Koo Kang,Albiruni R. Abdul Razak,Jonathan C. Trent,Steven Attia,Axel Le Cesne,Ying Su,Julie Meade,Tao Wang,Matthew L. Sherman,Rodrigo Ruiz-Soto,Michael C. Heinrich
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:40 (34): 3918-3928 被引量:36
标识
DOI:10.1200/jco.22.00294
摘要

PURPOSE Sunitinib, a multitargeted tyrosine kinase inhibitor (TKI), is approved for advanced gastrointestinal stromal tumor (GIST) after imatinib failure. Ripretinib is a switch-control TKI approved for advanced GIST after prior treatment with three or more TKIs, including imatinib. We compared efficacy and safety of ripretinib versus sunitinib in patients with advanced GIST who were previously treated with imatinib (INTRIGUE, ClinicalTrials.gov identifier: NCT03673501 ). PATIENTS AND METHODS Random assignment was 1:1 to once-daily ripretinib 150 mg or once-daily sunitinib 50 mg (4 weeks on/2 weeks off) and stratified by KIT/ platelet-derived growth factor α mutation and imatinib intolerance. The primary end point was progression-free survival (PFS) by independent radiologic review using modified Response Evaluation Criteria in Solid Tumors version 1.1. Secondary end points included objective response rate by independent radiologic review, safety, and patient-reported outcome measures. RESULTS Overall, 453 patients were randomly assigned to ripretinib (intention-to-treat [ITT], n = 226; KIT exon 11 ITT, n = 163) or sunitinib (ITT, n = 227; KIT exon 11 ITT, n = 164). Median PFS for ripretinib and sunitinib ( KIT exon 11 ITT) was 8.3 and 7.0 months, respectively (hazard ratio, 0.88; 95% CI, 0.66 to 1.16; P = .36); median PFS (ITT) was 8.0 and 8.3 months, respectively (hazard ratio, 1.05; 95% CI, 0.82 to 1.33; nominal P = .72). Neither was statistically significant. Objective response rate was higher for ripretinib versus sunitinib in the KIT exon 11 ITT population (23.9% v 14.6%, nominal P = .03). Ripretinib was associated with a more favorable safety profile, fewer grade 3/4 treatment-emergent adverse events (41.3% v 65.6%, nominal P < .0001), and better scores on patient-reported outcome measures of tolerability. CONCLUSION Ripretinib was not superior to sunitinib in terms of PFS. However, meaningful clinical activity, fewer grade 3/4 treatment-emergent adverse events, and improved tolerability were observed with ripretinib.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
miaomiaomiao发布了新的文献求助10
2秒前
sam发布了新的文献求助200
6秒前
Nakacoke77完成签到,获得积分10
6秒前
Murphy完成签到 ,获得积分10
18秒前
顾矜应助冷傲的灯泡采纳,获得10
24秒前
包容东蒽完成签到 ,获得积分10
26秒前
29秒前
赘婿应助科研通管家采纳,获得10
30秒前
科研通AI2S应助科研通管家采纳,获得10
30秒前
SciGPT应助科研通管家采纳,获得10
30秒前
morena应助科研通管家采纳,获得10
30秒前
Xiaoxiao应助科研通管家采纳,获得30
30秒前
今后应助VDC采纳,获得10
31秒前
横A完成签到 ,获得积分10
33秒前
46秒前
无私的枕头完成签到,获得积分10
46秒前
ling361完成签到,获得积分10
48秒前
VDC发布了新的文献求助10
51秒前
51秒前
meng发布了新的文献求助10
56秒前
妩媚的夜柳完成签到 ,获得积分10
58秒前
建立发布了新的文献求助10
59秒前
Lucas应助meng采纳,获得10
1分钟前
建立完成签到,获得积分10
1分钟前
土豆你个西红柿完成签到 ,获得积分10
1分钟前
景__完成签到 ,获得积分10
1分钟前
Bydoctor完成签到 ,获得积分10
1分钟前
火星上冥茗完成签到 ,获得积分10
1分钟前
Sue完成签到 ,获得积分10
1分钟前
阿敬完成签到,获得积分10
1分钟前
PositiveJugend完成签到,获得积分10
1分钟前
缓慢海蓝完成签到 ,获得积分10
1分钟前
科研毛毛虫完成签到,获得积分10
1分钟前
野原x之助完成签到 ,获得积分10
1分钟前
科研牛马完成签到,获得积分10
1分钟前
凯旋预言完成签到 ,获得积分10
1分钟前
柯语雪完成签到 ,获得积分10
1分钟前
Jasper应助飞白采纳,获得10
1分钟前
sam完成签到,获得积分10
1分钟前
高大凌寒发布了新的文献求助200
1分钟前
高分求助中
Production Logging: Theoretical and Interpretive Elements 2700
Neuromuscular and Electrodiagnostic Medicine Board Review 1000
こんなに痛いのにどうして「なんでもない」と医者にいわれてしまうのでしょうか 510
The First Nuclear Era: The Life and Times of a Technological Fixer 500
岡本唐貴自伝的回想画集 500
Distinct Aggregation Behaviors and Rheological Responses of Two Terminally Functionalized Polyisoprenes with Different Quadruple Hydrogen Bonding Motifs 450
Ciprofol versus propofol for adult sedation in gastrointestinal endoscopic procedures: a systematic review and meta-analysis 400
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 物理 生物化学 纳米技术 计算机科学 化学工程 内科学 复合材料 物理化学 电极 遗传学 量子力学 基因 冶金 催化作用
热门帖子
关注 科研通微信公众号,转发送积分 3671180
求助须知:如何正确求助?哪些是违规求助? 3228098
关于积分的说明 9778330
捐赠科研通 2938347
什么是DOI,文献DOI怎么找? 1609853
邀请新用户注册赠送积分活动 760473
科研通“疑难数据库(出版商)”最低求助积分说明 735976